Healthcare reform in the United States and China: pharmaceutical market implications

Journal of Pharmaceutical Policy and Practice

Ansuman Mohanty¹  Arthur Daemmrich¹ 

[1]Department of History and Philosophy of Science, University of Kansas School of Medicine, Kansas City, 66160 USA

关键词: Affordable care act;    Drug prices;    Health insurance;    Health policy;    Healthcare system;    Pharmaceutical industry;   

DOI  :  10.1186/2052-3211-7-9

学科分类：药理学

来源: BioMed Central

【 摘 要 】

Objectives

The United States and China are broadening health insurance coverage and increasing spending on pharmaceuticals, in contrast to other major economies that are reducing health spending and implementing a variety of drug price controls. This article analyzes the implications of health system reforms in the United States and China for national pharmaceutical markets. It follows a historical institutionalist approach that identifies path dependency in the design and operation of national health systems. On that basis, we estimate prescription sales for 2015 and 2020, analyze the sustainability of free-market pricing for drugs in the two countries, and assess future competitive dynamics in the pharmaceutical sector.

【 授权许可】

Unknown